



# Biocon Biologics in Brazil: Factsheet

Biocon Biologics is a leading global biosimilars company committed to addressing patients' needs for cost-effective, high-quality biosimilars.

#### 🖄 VISION

To be a global leader in biologics, delivering affordable access to innovative and inclusive healthcare solutions, transforming patients' lives.

#### VALUES

- Innovation & differentiation
- Quality through compliance & best practices
- Integrity and ethical behaviour
- Collaboration, teamwork and mutual respect
- Performance-driven culture

#### **Company Profile**

Biocon Biologics is a unique, fully integrated, global biosimilars company with world-class 'lab to market' capabilities across development, manufacturing, and marketing. It is present in over 120 countries, including over 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.

In the Latin America (LATAM) region, Biocon Biologics is making a significant impact on patients' lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its 8 commercialized biosimilars.

Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology. It addresses the needs of patients in the LATAM region through its state-of-the-art manufacturing infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India, and insulins in Johor, Malaysia.


In Brazil, Biocon Biologics operates from its office in São Paulo. Through its self-led and partner-led commercial models, the company is focused on broadening access to biosimilars for treating cancer, diabetes and autoimmune disease through eight of its products for the benefit of patients and improving healthcare outcomes in Brazil.

Headquartered in Bengaluru, India, Biocon Biologics has a longstanding presence in the biosimilars industry, having invested over \$1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner Viatris has further strengthened Biocon Biologics' commercial presence in Brazil. As a trusted and reliable company, Biocon Biologics is poised to grow and consolidate its leadership in biosimilars in Brazil, making a meaningful impact on patients' lives.

# Transforming Healthcare. Transforming Lives.

### The Biocon Biologics Advantage

- PATIENT-CENTRICITY: Dedicated to expanding patient reach and generating significant savings for patients, payers, and healthcare systems.
- LAB-TO-MARKET EXPERTISE: Fully integrated from biosimilars development to manufacturing, distribution, and commercialization.
- LEGACY OF SUCCESS: Achieved several industry firsts with U.S. approvals for biosimilar Trastuzumab, biosimilar Pegfilgrastim, and interchangeable biosimilar Insulin Glargine.
- UNIQUE PORTFOLIO: A comprehensive and differentiated portfolio of biosimilars, including insulins, monoclonal antibodies, and conjugated recombinant proteins.
- GLOBAL SCALE PRODUCTION: Operates three large-scale, globally compliant biosimilars manufacturing facilities, ranking among the top 15\* companies worldwide in biomanufacturing capacity.
- WIDE COMMERCIAL FOOTPRINT: Commercialized products in 120+ countries through a combination of direct presence, strategic partnerships, and distributors.
- HIGH QUALITY & COMPLIANCE STANDARDS: Manufacturing facilities have received 80+ cGMP approvals from over 25 agencies, including the U.S. FDA and EMA.



## 4A Model of Enabling Health Equity

- Affordability: Rationalizing treatment costs while improving healthcare outcomes.
- Availability: Ensuring reliable product supplies across Advanced and Emerging Markets.
- Accessibility: Maximizing patient reach through country-specific self and partner-led commercial models.
- Assurance: Establishing a trustworthy brand that stands for the highest global quality.

# Our Products in Brazil

Brand Name	Molecules
Insugen	Rh-Insulin*
Zedora	Trastuzumab**
Abevmy	Bevacizumab
Fulphila	Pegfilgrastim
Simbeva	Bevacizumab***
Pegneucyte	Pegfilgrastim***
Hulio	Adalimumab
Nepexto	Etanercept

\* Commercialized by our partner Aspen in Brazil; \*\* Commercialized by our partner Libbs in Brazil; \*\*\* Commercialized by our partner Teuto in Brazil.

For more information: Biocon Biologics Corporate Factsheet Website: https://www.bioconbiologics.com



\*19th Annual Report of BioPlan Associates

### Global Portfolio

Trastuzumab	Insulin Glargine
Bevacizumab	Insulin Aspart
Pegfilgrastim	Adalimumab
rh-Insulin	Etanercept

#### **Biocon Biologics in Brazil**

#### **Business Partnership**

Marcelo Dos Santos Commercial Head, LATAM Region Email: marcelo.dossantos@biocon.com

### Media

#### Seema Ahuja

Global Head of Corporate Brand & Head of Communications – EMs Email: seema.ahuja@biocon.com

Last updated on: September 2024

Susheel Umesh Chief Commercial Officer, Emerging Markets Email: susheel.umesh@biocon.com

#### **Adverse Events**

#### Email:

medical.informationBrazil@biocon.com Ph: +55 800 8914130

Transforming Healthcare. Transforming Lives.